Alpha Lipoic Acid (ALA) for Numbness

Alpha-lipoic acid at 600mg daily improves neuropathic symptom scores in diabetic peripheral neuropathy. It works better on positive symptoms like burning than on sensory loss.

Overview

Alpha-lipoic acid at 600mg daily improves neuropathic symptom scores in diabetic peripheral neuropathy. It works better on positive symptoms like burning than on sensory loss.

Verdict

Mixed evidence

Alpha-lipoic acid has reasonable evidence for the burning and paraesthesia of diabetic neuropathy, weaker evidence for numbness itself.

How It Works

A potent antioxidant regenerating glutathione and vitamin C, it reduces oxidative and nitrosative stress in nerve tissue and improves endoneurial blood flow — the pathways implicated in hyperglycaemic nerve injury.

Dosing & Protocol

Typical dose

Recommended dose: 600mg daily, oral
Expected timeframe: Symptom improvement typically appears over three to five weeks.

Protocol

form: Racemic or R-alpha-lipoic acid
notes: Higher doses increase nausea without added benefit
timing: 30 minutes before food for absorption
duration: 3 months before judging
starting dose: 600mg once daily

Evidence

What the studies say

The SYDNEY 2 trial found 600mg oral daily improved Total Symptom Score versus placebo over five weeks, with higher doses adding side effects but not benefit. The four-year NATHAN 1 trial missed its primary composite endpoint but showed improvement in clinical impairment scores in a prespecified subgroup. Meta-analyses support symptomatic benefit for pain, burning and paraesthesia, with weaker and less consistent effects on objective sensory loss and nerve conduction.

Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial

Score: 9/10

2011

rct

n=460

Ziegler D, Low PA, Litchy WJ +3 more

Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy.

View source

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial

Score: 8/10

2006

rct

n=181

Ziegler D, Ametov A, Barinov A +3 more

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

View source

Safety

Caveats

Can lower blood glucose — monitor if on insulin or sulfonylureas. Nausea is dose-related. Does not substitute for glycaemic control, which remains the primary intervention.

Less likely to help if

People with non-diabetic neuropathy, compressive causes, or predominantly numb rather than painful presentations often see little change.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.